<DOC>
	<DOCNO>NCT00003849</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody locate cancer cell either kill deliver cancer-killing substance . PURPOSE : Phase II trial study effectiveness rituximab treat patient non-Hodgkin 's lymphoma Hodgkin 's disease .</brief_summary>
	<brief_title>Rituximab Treating Patients With Non-Hodgkin 's Lymphoma Hodgkin 's Disease</brief_title>
	<detailed_description>OBJECTIVES : I . Determine response rate ( complete partial ) rituximab previously untreated patient stage III IV CD20+ B-cell follicular small cleave cell non-Hodgkin 's lymphoma . II . Determine response rate ( complete partial ) rituximab patient relapse CD20+ Hodgkin 's disease . III . Determine time progression time chemotherapy patient treatment rituximab . OUTLINE : Patients stratify accord disease ( follicular small cleave cell non-Hodgkin 's lymphoma v relapse Hodgkin 's disease ) . Patients receive rituximab IV 4-6 hour day 1 weekly 4 week . Patients follow 1 , 3 , 6 , 9 , 12 month , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : A total 21-32 patient accrue arm study within 7-10.5 month .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven stage IIIA stage IVA Bcell follicular small cleave cell nonHodgkin 's lymphoma Tumor cell express CD20 No prior chemotherapy radiotherapy Stable disease would otherwise observed OR Histologically proven relapse Hodgkin 's disease stage Tumor cell express CD20 Bidimensionally measurable disease Masses ( e.g. , enlarge lymph node ) must least 1.5 cm X 1.5 cm CT , MRI , xray Splenic enlargement consider measurable spleen palpable least 3 cm leave costal margin No CNS lymphoma PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : No 5,000 circulate tumor cell Hepatic : Not specify Renal : Not specify Other : Not pregnant nursing Fertile patient must use effective contraception least 12 month follow study HIV negative No active malignancy PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
</DOC>